Oral supplementation with Leu-Ile, a hydrophobic dipeptide, prevents the impairment of memory induced by amyloid beta in mice via restraining the hyperphosphorylation of extracellular signal-regulated kinase.
Restraining the toxic pathways of amyloid beta peptide (Abeta) by daily supplementation with dietary products has been shown effective in preventing cognitive decline. In this study, we examined the effects of the orally administered Leu-Ile, a hydrophobic dipeptide, on the neurotoxicity of Abeta(25-35) in mice. Chronic daily treatment with Leu-Ile prevented the Abeta(25-35)-induced protein nitration and impairment of novel object recognition memory in mice. Protein nitration in the hippocampus induced by Abeta(25-35) was associated with the hyperphosphorylation of extracellular signal-regulated kinase (ERK) which was found responsible for the over-expression of inducible nitric oxide synthase. Sub-chronic treatment with Leu-Ile prevented the Abeta(25-35)-induced hyperphosphorylation of ERK and protein nitration in the hippocampus. The results suggested that with the protective property against the neurotoxicity of Abeta(25-35), Leu-Ile could be considered as a candidate for the dietary supplementation in the prevention of Abeta-related impairment of recognition memory.
Alkam
Tursun
T
Department of Neuropsychopharmacology & Hospital Pharmacy, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Nitta
Atsumi
A
Furukawa-Hibi
Yoko
Y
Niwa
Minae
M
Mizoguchi
Hiroyuku
H
Yamada
Kiyofumi
K
Nabeshima
Toshitaka
T
D000284:Administration, Oral; D000607:Aminoacetonitrile / Q000031:analogs & derivatives / Q000494:pharmacology; D016229:Amyloid beta-Peptides; D000818:Animals; D019208:Brain-Derived Neurotrophic Factor / Q000235:genetics / Q000378:metabolism; D004195:Disease Models, Animal; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005106:Exploratory Behavior / Q000187:drug effects; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism*; D005786:Gene Expression Regulation / Q000187:drug effects; D006624:Hippocampus / Q000187:drug effects / Q000378:metabolism; D007532:Isoleucine / Q000008:administration & dosage; D007930:Leucine / Q000008:administration & dosage; D008297:Male; D008569:Memory Disorders / Q000139:chemically induced* / Q000473:pathology / Q000517:prevention & control*; D051379:Mice; D008813:Mice, Inbred ICR; D052247:Nitric Oxide Synthase Type II / Q000235:genetics / Q000378:metabolism; D009842:Oligopeptides / Q000008:administration & dosage*; D010446:Peptide Fragments; D010766:Phosphorylation / Q000187:drug effects; D021641:Recognition, Psychology / Q000187:drug effects; D013997:Time Factors
D016229:Amyloid beta-Peptides; D019208:Brain-Derived Neurotrophic Factor; D004791:Enzyme Inhibitors; D009842:Oligopeptides; D010446:Peptide Fragments; C424127:SL 327; C074636:amyloid beta-protein (25-35); D007532:Isoleucine; D000607:Aminoacetonitrile; D052247:Nitric Oxide Synthase Type II; D048049:Extracellular Signal-Regulated MAP Kinases; D007930:Leucine